Full-length MSP1 as a malaria vaccine: is there hope?
Successful immunisation studies in monkeys based on MSP1 involved the use of the full-length protein as a malaria vaccine. However, unsuccessful human trials only tested MSP1 subunits. We explore the potential of SumayaVac-1 to broadly stimulate immune mechanisms associated with protection.
